Denosumab for Primary Osteoporosis and Its Impact on Sarcopenia in the Chinese Population: Insights from Clinical Evidence and RANKL Pathway Mendelian Randomization
Denosumab effectively treats osteoporosis and improves muscle function in Chinese patients. Genetic evidence supports a causal role of the RANKL pathway in sarcopenia, indicating that RANKL overexpression may contribute to its development. By integrating clinical and genetic evidence, our findings suggest that denosumab may represent a promising therapeutic option for patients with concurrent osteoporosis and sarcopenia.
Authors
- Shaotian Li (ORCID: https://orcid.org/0009-0002-1155-0625)
- Wen Peng (ORCID: https://orcid.org/0000-0003-2085-2422)
- Jingjing Wan (ORCID: https://orcid.org/0000-0001-9324-2647)
- Guqiao Nie (ORCID: https://orcid.org/0000-0002-5467-6431)
- Jingfeng Zou (ORCID: https://orcid.org/0009-0001-7305-7863)
- Xiong Ku
- Mi Yan
- Jiajia Ran (ORCID: https://orcid.org/0009-0007-0534-0361)
- Shanshan Hu (ORCID: https://orcid.org/0000-0002-9014-4168)
- Yan Yin (ORCID: https://orcid.org/0000-0002-7266-3554)
- Xiaoli Zheng
- Chunhui Tian (ORCID: https://orcid.org/0009-0000-6453-6996)
- Xin Yang (ORCID: https://orcid.org/0009-0002-6190-2588)
- Yiting Liu (ORCID: https://orcid.org/0009-0006-0620-3847)
- Yun Liu (ORCID: https://orcid.org/0000-0002-8158-3783)
- Liping Wang (ORCID: https://orcid.org/0000-0002-3750-8946)
Institutions
- Wuhan Union Hospital (CN)
- Wuhan University of Science and Technology (CN)
Publication Details
- Journal
- Clinical Interventions in Aging
- Published
- 2025-11-01
- DOI
- https://doi.org/10.2147/cia.s547803
- Citations
- 1
- Primary Topic
- Bone Metabolism and Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- Huazhong University of Science and Technology
- Tongji University
- Wuhan University
- Wuhan University of Science and Technology